The Experts below are selected from a list of 126 Experts worldwide ranked by ideXlab platform
Paul J Davis - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Hormone in the Clinic and Breast Cancer
Hormones and Cancer, 2018Co-Authors: Aleck Hercbergs, Shaker A Mousa, Matthew Leinung, Paul J DavisAbstract:There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-Thyroxine (T_4) in patients with advanced solid tumors, including breast cancer, has favorably affected the course of the cancer, particularly when coupled with administration of exogenous 3,5,3′-triiodo-L-thyronine (T_3) (euthyroid hypoThyroxinemia). We discuss in the current brief review the possible clinical settings in which to consider whether endogenous thyroid hormone—or exogenous thyroid hormone in the patient with hypothyroidism and coincident breast cancer—is significantly contributing to breast cancer outcome.
-
thyroid hormones as modulators of immune activities at the cellular level
Thyroid, 2011Co-Authors: Paolo De Vito, Sandra Incerpi, Jens Z Pedersen, P Luly, Faith B Davis, Paul J DavisAbstract:Background: Increasing evidence suggests that thyroid hormones, L-Thyroxine (T4) and 3,3′,5-triiodo-L-thyronine (T3), are modulators of the immune response. In monocytes, macrophages, leukocytes, n...
-
membrane receptor for thyroid hormone physiologic and pharmacologic implications
Annual Review of Pharmacology and Toxicology, 2011Co-Authors: Faith B Davis, Shaaban A Mousa, Paul J Davis, Mary K LuidensAbstract:Plasma membrane integrin αvβ3 is a cell surface receptor for thyroid hormone at which nongenomic actions are initiated. L-Thyroxine (T4) and 3,3′,5-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via the receptor. Tetraiodothyroacetic acid (tetrac), a deaminated T4 derivative, blocks the nongenomic proliferative and proangiogenic actions of T4 and T3. Acting at the integrin independently of T4 and T3, tetrac and a novel nanoparticulate formulation of tetrac that acts exclusively at the cell surface have oncologically desirable antiproliferative actions on multiple tumor cell survival pathway genes. These agents also block the angiogenic activity of vascular growth factors. Volume and vascular support of xenografts of human pancreatic, kidney, lung, and breast cancers are downregulated by tetrac formulations. The integrin αvβ3 receptor site for thyroid hormone selectively regulates signal transduction pathways and distinguishes between unmodified tetrac and the nanoparticulate fo...
-
l Thyroxine vs 3 5 3 triiodo l thyronine and cell proliferation activation of mitogen activated protein kinase and phosphatidylinositol 3 kinase
American Journal of Physiology-cell Physiology, 2009Co-Authors: Heng Yuan Tang, Mary K Luidens, Sandra Incerpi, Faith B Davis, Shaker A Mousa, George L Drusano, Paul J DavisAbstract:3,5,3′-Triiodo-l-thyronine (T3), but not l-Thyroxine (T4), activated Src kinase and, downstream, phosphatidylinositol 3-kinase (PI3-kinase) by means of an αvβ3 integrin receptor on human glioblasto...
Arthur J Prange - One of the best experts on this subject based on the ideXlab platform.
-
effects of Thyroxine as compared with Thyroxine plus triiodothyronine in patients with hypothyroidism
The New England Journal of Medicine, 1999Co-Authors: Robertas Bunevicius, Gintautas Kazanavicius, R Zalinkevicius, Arthur J PrangeAbstract:A BSTRACT Background Patients with hypothyroidism are usually treated with Thyroxine (levoThyroxine) only, although both Thyroxine and triiodothyronine are secreted by the normal thyroid gland. Whether thyroid secretion of triiodothyronine is physiologically important is unknown. Methods We compared the effects of Thyroxine alone with those of Thyroxine plus triiodothyronine (liothyronine) in 33 patients with hypothyroidism. Each patient was studied for two five-week periods. During one period, the patient received his or her usual dose of Thyroxine. During the other, the patient received a regimen in which 50 µg of the usual dose of Thyroxine was replaced by 12.5 µg of triiodothyronine. The order in which each patient received the two treatments was randomized. Biochemical, physiologic, and psychological tests were performed at the end of each treatment period. Results The patients had lower serum free and total Thyroxine concentrations and higher serum total triiodothyronine concentrations after treatment with Thyroxine plus triiodothyronine than after Thyroxine alone, whereas the serum thyrotropin concentrations were similar after both treatments. Among 17 scores on tests of cognitive performance and assessments of mood, 6 were better or closer to normal after treatment with Thyroxine plus triiodothyronine. Similarly, among 15 visual-analogue scales used to indicate mood and physical status, the results for 10 were significantly better after treatment with Thyroxine plus triiodothyronine. The pulse rate and serum sex hormone–binding globulin concentrations were slightly higher after treatment with Thyroxine plus triiodothyronine, but blood pressure, serum lipid concentrations, and the results of neurophysiologic tests were similar after the two treatments. Conclusions In patients with hypothyroidism, partial substitution of triiodothyronine for Thyroxine may improve mood and neuropsychological function; this finding suggests a specific effect of the triiodothyronine normally secreted by the thyroid gland. (N Engl J Med 1999;340:424-9.)
Faith B Davis - One of the best experts on this subject based on the ideXlab platform.
-
thyroid hormones as modulators of immune activities at the cellular level
Thyroid, 2011Co-Authors: Paolo De Vito, Sandra Incerpi, Jens Z Pedersen, P Luly, Faith B Davis, Paul J DavisAbstract:Background: Increasing evidence suggests that thyroid hormones, L-Thyroxine (T4) and 3,3′,5-triiodo-L-thyronine (T3), are modulators of the immune response. In monocytes, macrophages, leukocytes, n...
-
membrane receptor for thyroid hormone physiologic and pharmacologic implications
Annual Review of Pharmacology and Toxicology, 2011Co-Authors: Faith B Davis, Shaaban A Mousa, Paul J Davis, Mary K LuidensAbstract:Plasma membrane integrin αvβ3 is a cell surface receptor for thyroid hormone at which nongenomic actions are initiated. L-Thyroxine (T4) and 3,3′,5-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via the receptor. Tetraiodothyroacetic acid (tetrac), a deaminated T4 derivative, blocks the nongenomic proliferative and proangiogenic actions of T4 and T3. Acting at the integrin independently of T4 and T3, tetrac and a novel nanoparticulate formulation of tetrac that acts exclusively at the cell surface have oncologically desirable antiproliferative actions on multiple tumor cell survival pathway genes. These agents also block the angiogenic activity of vascular growth factors. Volume and vascular support of xenografts of human pancreatic, kidney, lung, and breast cancers are downregulated by tetrac formulations. The integrin αvβ3 receptor site for thyroid hormone selectively regulates signal transduction pathways and distinguishes between unmodified tetrac and the nanoparticulate fo...
-
l Thyroxine vs 3 5 3 triiodo l thyronine and cell proliferation activation of mitogen activated protein kinase and phosphatidylinositol 3 kinase
American Journal of Physiology-cell Physiology, 2009Co-Authors: Heng Yuan Tang, Mary K Luidens, Sandra Incerpi, Faith B Davis, Shaker A Mousa, George L Drusano, Paul J DavisAbstract:3,5,3′-Triiodo-l-thyronine (T3), but not l-Thyroxine (T4), activated Src kinase and, downstream, phosphatidylinositol 3-kinase (PI3-kinase) by means of an αvβ3 integrin receptor on human glioblasto...
Robertas Bunevicius - One of the best experts on this subject based on the ideXlab platform.
-
effects of Thyroxine as compared with Thyroxine plus triiodothyronine in patients with hypothyroidism
The New England Journal of Medicine, 1999Co-Authors: Robertas Bunevicius, Gintautas Kazanavicius, R Zalinkevicius, Arthur J PrangeAbstract:A BSTRACT Background Patients with hypothyroidism are usually treated with Thyroxine (levoThyroxine) only, although both Thyroxine and triiodothyronine are secreted by the normal thyroid gland. Whether thyroid secretion of triiodothyronine is physiologically important is unknown. Methods We compared the effects of Thyroxine alone with those of Thyroxine plus triiodothyronine (liothyronine) in 33 patients with hypothyroidism. Each patient was studied for two five-week periods. During one period, the patient received his or her usual dose of Thyroxine. During the other, the patient received a regimen in which 50 µg of the usual dose of Thyroxine was replaced by 12.5 µg of triiodothyronine. The order in which each patient received the two treatments was randomized. Biochemical, physiologic, and psychological tests were performed at the end of each treatment period. Results The patients had lower serum free and total Thyroxine concentrations and higher serum total triiodothyronine concentrations after treatment with Thyroxine plus triiodothyronine than after Thyroxine alone, whereas the serum thyrotropin concentrations were similar after both treatments. Among 17 scores on tests of cognitive performance and assessments of mood, 6 were better or closer to normal after treatment with Thyroxine plus triiodothyronine. Similarly, among 15 visual-analogue scales used to indicate mood and physical status, the results for 10 were significantly better after treatment with Thyroxine plus triiodothyronine. The pulse rate and serum sex hormone–binding globulin concentrations were slightly higher after treatment with Thyroxine plus triiodothyronine, but blood pressure, serum lipid concentrations, and the results of neurophysiologic tests were similar after the two treatments. Conclusions In patients with hypothyroidism, partial substitution of triiodothyronine for Thyroxine may improve mood and neuropsychological function; this finding suggests a specific effect of the triiodothyronine normally secreted by the thyroid gland. (N Engl J Med 1999;340:424-9.)
Mary K Luidens - One of the best experts on this subject based on the ideXlab platform.
-
membrane receptor for thyroid hormone physiologic and pharmacologic implications
Annual Review of Pharmacology and Toxicology, 2011Co-Authors: Faith B Davis, Shaaban A Mousa, Paul J Davis, Mary K LuidensAbstract:Plasma membrane integrin αvβ3 is a cell surface receptor for thyroid hormone at which nongenomic actions are initiated. L-Thyroxine (T4) and 3,3′,5-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via the receptor. Tetraiodothyroacetic acid (tetrac), a deaminated T4 derivative, blocks the nongenomic proliferative and proangiogenic actions of T4 and T3. Acting at the integrin independently of T4 and T3, tetrac and a novel nanoparticulate formulation of tetrac that acts exclusively at the cell surface have oncologically desirable antiproliferative actions on multiple tumor cell survival pathway genes. These agents also block the angiogenic activity of vascular growth factors. Volume and vascular support of xenografts of human pancreatic, kidney, lung, and breast cancers are downregulated by tetrac formulations. The integrin αvβ3 receptor site for thyroid hormone selectively regulates signal transduction pathways and distinguishes between unmodified tetrac and the nanoparticulate fo...
-
l Thyroxine vs 3 5 3 triiodo l thyronine and cell proliferation activation of mitogen activated protein kinase and phosphatidylinositol 3 kinase
American Journal of Physiology-cell Physiology, 2009Co-Authors: Heng Yuan Tang, Mary K Luidens, Sandra Incerpi, Faith B Davis, Shaker A Mousa, George L Drusano, Paul J DavisAbstract:3,5,3′-Triiodo-l-thyronine (T3), but not l-Thyroxine (T4), activated Src kinase and, downstream, phosphatidylinositol 3-kinase (PI3-kinase) by means of an αvβ3 integrin receptor on human glioblasto...